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Osteosarcomas remain one of the most commonly
occurring bone cancers in adolescents, accounting for
approximately 3% of all diagnosed childhood malignan-
cies. Approximately 30% of osteosarcoma patients
develop pulmonary metastatic disease, which is asso-
ciated with poor prognosis, as 5-year survival rates for
these patients are less than 20%. Cytotoxic T-lympho-
cytes (CTL) likely play an important role in the control
of developing osteosarcomas as polymorphisms in cyto-
toxic T lymphocyte antigen 4 (CTLA-4), an inhibitory
tumor necrosis factor receptor (TNFR) family member,
result in increased CTLA-4 protein expression levels,
and are associated with higher risk of developing osteo-
sarcoma. While CTLA-4 is involved in limiting the gen-
eration of CTL responses, other inhibitory TNFR family
members limit the function of CTL after tumor metas-
tases and during disease progression. In particular, liga-
tion of programmed death receptor-1 (PD-1), expressed
on tumor-specific CTL, by PD-1 ligand (PD-L1) on
tumors, results in potent inhibition of CTL proliferation,
cytokine production, and cytotoxicity, leading to tumor
progression. Using a mouse model of metastatic osteo-
sarcoma, we have shown that PD-1 is expressed on
osteosarcoma tumor infiltrating CTL, and that osteosar-
coma cells express PD-L1. Human metastatic osteosarco-
mas also exhibit increased expression of PD-L1
compared to pre-metastatic tumors, with PD-1 expres-
sion on metastatic tumor infiltrating lymphocytes.
Furthermore, we have shown that removal of PD-1/PD-
L1 interactions in the mouse metastatic osteosarcoma
models dramatically improves survival outcomes. These
studies of the role of PD-1 in inhibition of CTL-mediated
eradication in metastatic osteosarcoma in mouse models
and in primary human metastatic osteosarcoma provide
the necessary pre-clinical data required for subsequent
clinical testing of therapeutic approaches to block PD-1/
PD-L1 interactions for treatment of metastatic osteosar-
coma patients.
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